Compare the Renal Protective Effects of Febuxostat and Benzbromarone
NCT ID: NCT02338323
Last Updated: 2019-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
160 participants
INTERVENTIONAL
2015-01-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients
NCT02944214
The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients
NCT02338128
Effect of Hyperuricaemia on Chronic Renal Disease
NCT03425708
Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction
NCT03534037
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
NCT01350388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Febuxostat
take orally, 40mg per day, for 1 year
Febuxostat
It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
Benzbromarone
take orally, 50mg per day, for 1 year
Benzbromarone
It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Febuxostat
It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
Benzbromarone
It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Gout
2. Hyperuricemia patients without gout but have cardiovascular risk and serum uric acid \> 480umol/L
3. Hyperuricemia patients without gout but with serum uric acid \> 540umol/L
Exclusion Criteria
2. Liver dysfunction (Aspartate transaminase or/and alanine aminotransferase exceed 2 times of normal range)
3. Urinary tract obstruction
4. unstable angina, heart failure (stage III-IV, NYHA), new stroke, need diuretics for long-term treatment
5. Severe lung diseases or cancers
6. Pregnant woman or woman who prepare to be pregnant，nursing mothers
7. unable to sign informed consent form，or disagree with following-up
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai 10th People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ai Peng
Chief of department of Nephrology & Rheumatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ling Wang, MD, PhD
Role: STUDY_CHAIR
Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FB2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.